Helix and QIAGEN to jointly develop and commercialize companion diagnostics for hereditary diseases
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
Partnership to leverage the Helix Laboratory Platform and QIAGEN's biopharma relationships, NGS capabilities, and global regulatory expertise
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
QIAGEN has started its cloud transformation journey with the firm belief that cloud computing can be a key enabler of future business growth
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
Subscribe To Our Newsletter & Stay Updated